SCHEMBL260829

SCHEMBL260829

FC(F)(F)c1[c]c(Cl)ccc1

nearest known ligand 0.30

Predicted protein targets (top 2)

geneUniProtsupporting neighboursconfidence
ENPP3 O14638 1/20 0.30
ENPP1 P22413 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL262125 0.82 TSHR (0.36)
SCHEMBL2696387 0.76 CA2 (0.31)
SCHEMBL15353486 0.73 ALDH1A1 (0.31)
SCHEMBL148397 0.73 ALDH1A1 (0.31)
SCHEMBL4299 0.73
SCHEMBL11504024 0.71 CA2 (0.31)
SCHEMBL6221220 0.71 TSHR (0.37)
SCHEMBL1067884 0.71 RAPGEF4 (0.31)
SCHEMBL1068722 0.71 ENPP3 (0.30) ENPP3ENPP1
Benzene SCHEMBL8015826 0.70 TSHR (0.39)

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 415 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2024145505-A1 PYRIMIDINE CARBOXAMIDE COMPOUNDS ACRIVON THERAPEUTICS, INC. (US) 2024-07-04 WO claimed
US-11897891-B2 Tricyclic heterocycles as FGFR inhibitors INCYTE CORPORATION (US) 2024-02-13 US claimed
WO-2023192801-A1 SULFONAMIDO DERIVATIVES AS CYCLIN-DEPENDENT KINASE 2 INHIBITORS NIKANG THERAPEUTICS, INC. (US) 2023-10-05 WO claimed
WO-2021113479-A1 TRICYCLIC HETEROCYCLES AS FGFR INHIBITORS INCYTE CORPORATION (US) 2021-06-10 WO claimed
US-20210171535-A1 TRICYCLIC HETEROCYCLES AS FGFR INHIBITORS INCYTE CORPORATION 2021-06-10 US claimed
EP-3041825-B1 PROCEDURE FOR THE SYNTHESIS OF N-BENZYL-N-CYCLOPROPYL-1H-PYRAZOLE-4-CARBOXAMIDE DERIVATIVES BAYER CROPSCIENCE AG (DE) 2019-03-13 EP claimed
US-9656965-B2 Procedure for the synthesis of N-benzyl-N-cyclopropyl-1H-pyrazole-4-carboxamide derivatives BAYER CROPSCIENCE AKTIENGESELLSCHAFT (DE) 2017-05-23 US claimed
US-20170114053-A1 HETEROCYCLIC COMPOUNDS AND METHODS OF USE THEREOF THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERV (US) 2017-04-27 US claimed
EP-3154966-A1 HETEROCYCLIC COMPOUNDS AND METHODS OF USE THEREOF The U.S.A. As Represented By The Secretary, Department Of Health And Human Services (US) 2017-04-19 EP claimed
EP-3080090-A1 BICYCLIC HETEROARYL INDOLE ANALOGUES USEFUL AS ROR GAMMA MODULATORS Glenmark Pharmaceuticals S.A. (CH) 2016-10-19 EP claimed
EP-2077997-A1 PYRIDAZINE DERIVATIVES Syngeta Participations AG (CH) 2009-07-15 EP claimed
WO-2009080314-A1 PYRIDAZINE DERIVATIVES USEFUL AS FUNGICIDES AND FOR THE TREATMENT OF CANCER SYNGENTA PARTICIPATIONS AG (CH) 2009-07-02 WO claimed
WO-2008089934-A1 PYRIDAZINE DERIVATIVES, PROCESSES FOR THEIR PREPARATION AND THEIR USE AS FUNGICIDES SYNGENTA PARTICIPATIONS AG (CH) 2008-07-31 WO claimed
WO-2008049585-A1 PYRIDAZINE DERIVATIVES SYNGENTA PARTICIPATIONS AG (CH) 2008-05-02 WO claimed
WO-2008049584-A1 NOVEL PYRIDAZINE DERIVATIVES SYNGENTA PARTICIPATIONS AG (CH) 2008-05-02 WO claimed
US-5883044-A Herbicidal method utilizing phosphosulfonate herbicides and oxime ether safeners ROHM AND HAAS COMPANY (US) 1999-03-16 US claimed
EP-0699390-B1 Compositions containing phosphosulfonate herbicides and dichloroacetamide safeners, and method of use ROHM & HAAS (US) 1998-10-07 EP claimed
US-5693590-A PLANT GROWTH REGULATOR ROHM AND HAAS COMPANY (US) 1997-12-02 US claimed
EP-0699390-A2 Compositions containing phosphosulfonate herbicides and dichloroacetamide safeners, and method of use ROHM AND HAAS COMPANY (US) 1996-03-06 EP claimed
US-4125620-A HYPOTENSIVE BOEHRINGER INGELHEIM GMBH (DE) 1978-11-14 US claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11897891-B2 Tricyclic heterocycles as FGFR inhibitors FGFR3, FGFR1, FGFR2 ENPP3 1801/4885ENPP1 1460/4885
US-20170114053-A1 HETEROCYCLIC COMPOUNDS AND METHODS OF USE THEREOF HAVCR2, AR, AKR7A2 ENPP3 2525/4885ENPP1 2550/4885
US-20210171535-A1 TRICYCLIC HETEROCYCLES AS FGFR INHIBITORS FGFR3, FGFR1, FGFR2 ENPP3 1801/4885ENPP1 1460/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.